The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback